NCT01740570View on ClinicalTrials.gov

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2017

Conditions

Brain Cancer

Interventions

DRUG

Cabazitaxel

"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."